I kliniske undersøgelser måtte romiplostim- behandlingen seponeres hos fire ud af 271 patienter pga. aflejring af retikulin i knoglemarven.
In clinical studies, romiplostim treatment was discontinued in 4 of the 271 patients because of bone marrow reticulin deposition.